{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"groups":[{"description":"The subject received the PEGASYS at a dose level of 45 micrograms weekly and gradually increased to the maximum dose of 180 micrograms per week. The dose was administered by prefilled syringes and injected subcutaneously. Subjects received therapy for up to 12 months.\n\nAspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.","id":"OG000","title":"PEGASYS"},{"description":"Subjects received a 500mg tablet to be taken twice daily for up to 12 months of treatment.\n\nAspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.","id":"OG001","title":"Hydroxyurea"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"4 years","title":"Number of Participants With Major Cardiovascular Events After Therapy","type":"SECONDARY","unitOfMeasure":"Participants"}